Literature DB >> 9181397

Nosocomial respiratory syncytial virus infections: prevention and control in bone marrow transplant patients.

R Garcia1, I Raad, D Abi-Said, G Bodey, R Champlin, J Tarrand, L A Hill, J Umphrey, J Neumann, J Englund, E Whimbey.   

Abstract

OBJECTIVE: To assess the effectiveness of a multifaceted infection control strategy in limiting the nosocomial transmission of respiratory syncytial virus (RSV) infection to patients in a bone marrow transplant (BMT) unit.
DESIGN: Before/after trial.
SETTING: University-affiliated tertiary cancer center. PATIENTS: Adult BMT recipients hospitalized during two consecutive wintertime community outbreaks of RSV infection.
INTERVENTIONS: An infection control strategy against nosocomial RSV infection was implemented in the BMT unit in February 1993. The strategy involved prompt identification, isolation, and cohorting of RSV-infected patients; prompt therapy with aerosolized ribavirin; use of masks and gloves by anyone entering an infected BMT patient's room; screening visitors for respiratory symptoms; restricting visitation by all children under 12 years of age and all family members and other visitors with RSV symptoms; and restricting symptomatic hospital staff from working in the BMT unit.
RESULTS: After implementation of the multifaceted infection-control strategy, there were four cases of nosocomial RSV infection in 3,870 patient days (incidence density, 1.0 case/1,000 patient days) compared with 14 cases of nosocomial RSV infection in 3,152 patient days (incidence density, 4.4 cases/1,000 patient days) during the 1992-1993 RSV season (rate ratio, 4.4; 95% confidence interval [CI95]. 1.4-17.9: P < .01). This decrease in incidence occurred despite a comparable prevalence of community-acquired RSV cases between the two seasons (2.2% vs 3.2% in 1992-1993 and 1993-1994, respectively; prevalence ratio, 0.7; CI95, 0.2-2.1; P = 0.5).
CONCLUSION: Institution of a multifaceted infection control strategy significantly reduced the frequency of nosocomial RSV infection in a high-risk group of adult BMT recipients.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9181397     DOI: 10.1086/647640

Source DB:  PubMed          Journal:  Infect Control Hosp Epidemiol        ISSN: 0899-823X            Impact factor:   3.254


  15 in total

1.  A prospective surveillance of nosocomial respiratory syncytial virus infection in a hematology ward: a single-center experience in Japan.

Authors:  M Kami; Y Kishi; T Hamaki; Y Maruta; E Kusumi; H Iwata; J I Ueyama; S Miyakoshi; S I Morinaga; Y Mutou
Journal:  Int J Hematol       Date:  2001-10       Impact factor: 2.490

2.  2007 Guideline for Isolation Precautions: Preventing Transmission of Infectious Agents in Health Care Settings.

Authors:  Jane D Siegel; Emily Rhinehart; Marguerite Jackson; Linda Chiarello
Journal:  Am J Infect Control       Date:  2007-12       Impact factor: 2.918

3.  Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective.

Authors:  Marcie Tomblyn; Tom Chiller; Hermann Einsele; Ronald Gress; Kent Sepkowitz; Jan Storek; John R Wingard; Jo-Anne H Young; Michael J Boeckh; Michael A Boeckh
Journal:  Biol Blood Marrow Transplant       Date:  2009-10       Impact factor: 5.742

Review 4.  Respiratory syncytial virus infection in adults.

Authors:  A R Falsey; E E Walsh
Journal:  Clin Microbiol Rev       Date:  2000-07       Impact factor: 26.132

5.  Orally active fusion inhibitor of respiratory syncytial virus.

Authors:  Christopher Cianci; Kuo-Long Yu; Keith Combrink; Ny Sin; Bradley Pearce; Alan Wang; Rita Civiello; Stacey Voss; Guangxiang Luo; Kathy Kadow; Eugene V Genovesi; Brian Venables; Hatice Gulgeze; Ashok Trehan; Jennifer James; Lucinda Lamb; Ivette Medina; Julia Roach; Zheng Yang; Lisa Zadjura; Richard Colonno; Junius Clark; Nicholas Meanwell; Mark Krystal
Journal:  Antimicrob Agents Chemother       Date:  2004-02       Impact factor: 5.191

6.  Nosocomial transmission of respiratory syncytial virus in an outpatient cancer center.

Authors:  Helen Y Chu; Janet A Englund; Sara Podczervinski; Jane Kuypers; Angela P Campbell; Michael Boeckh; Steven A Pergam; Corey Casper
Journal:  Biol Blood Marrow Transplant       Date:  2014-03-06       Impact factor: 5.742

7.  Clinical characterisation and phylogeny of respiratory syncytial virus infection in hospitalised children at Red Cross War Memorial Children's Hospital, Cape Town.

Authors:  Regina Oladokun; Rudzani Muloiwa; Nei-Yuan Hsiao; Ziyaad Valley-Omar; James Nuttall; Brian Eley
Journal:  BMC Infect Dis       Date:  2016-05-31       Impact factor: 3.090

Review 8.  Risk of nosocomial respiratory syncytial virus infection and effectiveness of control measures to prevent transmission events: a systematic review.

Authors:  Clare E French; Bruce C McKenzie; Caroline Coope; Subhadra Rajanaidu; Karthik Paranthaman; Richard Pebody; Jonathan S Nguyen-Van-Tam; Julian P T Higgins; Charles R Beck
Journal:  Influenza Other Respir Viruses       Date:  2016-03-24       Impact factor: 4.380

Review 9.  The infectious march: the complex interaction between microbes and the immune system in asthma.

Authors:  Terianne Wong; Gary Hellermann; Shyam Mohapatra
Journal:  Immunol Allergy Clin North Am       Date:  2010-11       Impact factor: 3.479

Review 10.  Molecular epidemiology of respiratory viruses in virus-induced asthma.

Authors:  Hiroyuki Tsukagoshi; Taisei Ishioka; Masahiro Noda; Kunihisa Kozawa; Hirokazu Kimura
Journal:  Front Microbiol       Date:  2013-09-12       Impact factor: 5.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.